• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to a new process for the manufacture of 7,16-dioxa-2-aza-10-0-cladinosyl-12-0-desosaminyl-4,5-dihydroxy-6-ethyl-3,5,9,11,13,15-hexamethyl- bicycio[11.2.1]-hexadeca-1(2)-ene-8-one, a semisynthetic macrolide antibiotic of the erythromycin A series, by means of Beckmann rearrangement of erythromycin A oxime monohydrochloride or dihydrochloride with aromatic sulfochlorides of the formula 4-R-C6H4SO2Cl, wherein R stands for C1-C3 alkyl, halogen, acylamino of the formula -NHCOR,, wherein R1 stands for C1-C3 alkyl, in the presence of bases, without preliminary isolation of erythromycin A oxime. There is also provided a novel imtermediate erythromycin A oxime dihydrochloride and the preparation thereof from erythromycin A with hydroxylamine hydrochloride.
    公开号:SU1447288A3
    申请号:SU843767328
    申请日:1984-07-18
    公开日:1988-12-23
    发明作者:Лопотар Невенка；Кобрехель Габриела；Цориц Миленко；Джокиц Слободан
    申请人:Соур Плива Фармацеитска,Кемийска,Прехрамбена И Козметичка Индустрия,Н.Сол.О. (Фирма)；
    IPC主号:
    专利说明:


    CM
    This invention relates to an improved process for the preparation of a polysynthetic macrolide antibiotic erythromycin of series A of formula C
    snSnz, 2
    N (CH5) 2
    Ys
    BUT
    about
    ..
    at
    SNS / 1 ..- 0
     t ° ok
     CH;
    The purpose of the invention is to increase the yield of the target product and simplify the process by using a new intermediate product, erythromycin hydroxyhydrochloride, which is obtained by oximating erythromycin A in an acidic medium.
    Example 1. Erythromycin A oxime dihydrochloride,
    To a solution of erythromycin A (666 g; 0.907 mol) in methanol (3330 ml), hydrochloride hydrochloride (312 g; 4.489 mol and sodium carbonate SiCC (79.5 g, 0.745 mol)) is added with stirring and boiled. the mixture is kept under reflux for 10 h. The reaction mixture is filtered (pH 5.8), the precipitate is washed several times with hot methanol and the combined methanol filtrates are concentrated to 1/3 of the original volume by evaporation under reduced pressure. The reaction mixture is left to crystallize for 24 hours, the precipitated crystalline product is filtered, washed with cold methanol and dried at room temperature in a vacuum dryer. Receive 570 g (76.4%) of the erythromycin oxime dihydrochloride A. T. pl. 140-145 ° C. 1 ° - 50.29 ° (1%, CH, OH).
    IR (KBr): 1725 (, lactone) and 1639 cm- (C N).
     H NMR (JtMCO-d): 2.67 ppm (s, 6H, -N / CH / i).
    pK 7.3 (dimethylformamide - water a, 66%).
    RC 0.41 (sec. Butanol - nitromethane - ethyl 1setat - water 6: 3: 2: 2)
    Calculated,%: C1 8.63.
    Found,%: C1 8.08.
    with
    ten
    15
    20
    25
    ..) 40
    45
    50
    PRI mme R 2. Dihydrohlo1) id erythromycin A oxime (method B),
    From a mixture containing 666 g (0.907 mol) of erythromycin A dissolved in 3330 ml of methanol, 312 g (4.489 mol) of hydroxylaminohydrochloride and 321 g (1.266 mol) of Rari carbonate in Example I, 563 g (75.5%) are separated. a product that has the same physicochemical constants.
    Example 3 p. 7,6-Dioxa-2-aza-10-0-cladinosyl-12-0-desosaminyl-4, 5-dihydroxy-b-ethyl-3,5,9,1 1, 1 3, 1 5-hexamethylbicyclo l1,2,1J hexadeca-1 (2) -en-8-one.
    Solutions of p-toluene sulfochloride (2.32 g; 0.0122 mol) in acetone (20 ml) and NaHCO (2.55 g, 0.0303 mol) in water (60 ml) are added dropwise over 30 minutes at a temperature of from 0 to 5 ° С in suspension of 5.0 g (0.00608 mol) of erythromycin A oxime dihydrochloride in acetone (50 ml). The reaction mixture is stirred for another 3 hours at the same temperature, the acetone is evaporated under reduced pressure, and to the resulting aqueous suspension 0 ml of chloroform (pH 7.3) is added, and then the pH is adjusted to 5.5 by acidification with 2 NHC1. The layers are separated and the aqueous layer is extracted twice with chloroform (10 ml). The extraction was repeated at pH 6.0 (3 x 10 ml) and pH 8.0 (3 x 20 ml), and the combined extracts were dried over and evaporated to dryness, at pH 8.0, 3.3 (74.3%) a) chromatographically homogeneous product with RJ 0.22 (n-butanol-acetic acid-water 4: 1: 5). T.} 1l.128-131 C.
    IR (CHCl): 1725 (, lactone) and 1705 cm - ();
     NMR (CDCl1): 178.1 (s „C-8); 163.9 (s, C-1) and 87.3 ppm (s, C-13). M 730..
    PRI me R 4. 7,16-Diox-2-aza-10-0-cladinosyl-12-0-desosaminyl-4,5-dihydroxy-6-ethyl-3, 5, 9, 1, 1 3 , 15-hexamethylbicyclo 11,2,13 hexa-1-d (2) -en-8-one (method 3).
    To a suspension of erythromycin A oxime cyhydrochloride (5.0 rj 0.00608 mol) in acetone (50 ml) was added trizthylamine (3.074 g, 0.03074 mol), and then dropwise, under stirring, at a temperature from 0 to 5 ° From R, a solution of p-toluenesulfonyl chloride (2.32 g; 0.01216 mol) in acetone (20 ml) was added over 30 minutes. The reaction mixture is stirred for 2 hours at the same temperature and left for 24 hours at room temperature. Acetone is evaporated under reduced pressure, the remaining residue is suspended in 50 ml of water and 10 ml of chloroform (pH 7.7) and extracted with a gradient pH extraction with chloroform at pH 5.5 (3 x X 10 ml) and at pH 8.0 (3 X 20 ml). After drying the combined organic extracts over K, CO 2 and evaporation of chloroform at pH 8.0, 2.94 g (66.1%) of the product is obtained with the same physicochemical constants as given in Example 3.
    PRI me R 5. 7,16-Diox-2-aza-10-0-cladinosyl-12-0-desosaminyl-4,5-dihydroxy-6-ethyl-3,5,9,11,13, 15-hexamethylbicyclo 11,2,1 hexadeca-1 (2) -en-8-one (method 5).
    Using as a starting material 5.0 g (0.00608 mol) of erythromycin A oxime hydrochloride, suspended in acetone (50 ml), 7.35 g (0.0243 mol) of p-iodobenzene sulfonyl chloride dissolved in 70 ml acetone, and 10.22 g (0.122 mol) of NaHCOj, dissolved in 210 ml of water, are obtained and recovered according to Example 3 2.98 g (66.9%) of the product with the same physicochemical constants as given in Example 3 .
    PRI me R 6. 7,16-Diox-2-aza-10-0-cladinosyl-12-0-desosaminyl-4,5-dihydroxy-b-ethyl-3, 5,9,11,13, 15-hexamethylbicyclo 11,2,1 hexa-deca-1 (2) -en-8-one (method 6).
    Using as a starting material 5.0 g (0.00608 mol) of erythromycin A oxime hydrochloride, suspended in 50 ml of acetone, 2.84 g (0.0122 mol) of p-acetamine benzene sulfonyl chloride dissolved in 180 ml of acetone-water (1: 1) and 2.55 g (0.0304 mol) of NaHCD, dissolved in 90 ml of water, are obtained and recovered in Example 3 of 2.73 g (61.4%) of the product with the same physic - chemical constants, as given in example 3.
    PRI me R 7. 7,16-Diox-2-aza-10-0-cladinosyl-12-0-desosaminyl-4,5-dihydroxy-b-ethyl-3, 5,9, P, 13, 15-hexamethylbicyclo 11,2,1 hexadeca-1 (2) -en-8-one (method 7).
    To a solution of erythromycin A (55.6 g; 0.076 mol) in methanol (280 ml) is added with stirring hydroxyl-,
    amino hydrochloride (26.01 rjO, 373 mol) and sodium carbonate SiCC (6.62 g; 0.062 mol), after which the solution is maintained at boiling point for 1 V with reflux condenser. The methanol is separated by distillation under reduced pressure (about 2/3 volume), and the concentrated reaction suspension is left to crystallize for 24 hours at
    temperature from 0 to, filtered and washed with cold methanol. The resulting crystalline product (52.7 g) is suspended in acetone (525 ml), the reaction suspension is cooled to a temperature from 0 to 5 ° C, after which p-toluenesulfonic chloride (24.4 g; 0.128 mol), dissolved in acetone
    (210 ml) and mixed with a solution of NaHCO (21.5 g; 0.526 mol) and in water (630 ml). The reaction mixture was stirred for another 3 hours at the same temperature, acetone was scrubbed and the product was separated by a gradient pH extraction of Example 3. The yield was 34.7 g (62.2%), and the product showed the same physicochemical constants as given. in example 3.
    Example8. 7,16-Dioxa-2-aza-10-0-cladinosyl-12-0-desosaminyl-4,5-dihydroxy-b-ethyl-3, 5,9,11,13, 15-hexamethylbicyclo | 1,2, 1 hexa-deca-1 (2) -en-8-one (method 8).
    Erythromycin A oxime dihydrochloride (30.7 g) obtained in Example 7 is suspended in acetone (470 ml) and water (200 ml), cooled from O to, after which the resulting suspension is added, with stirring, for 1 hour in portions solid p-acetylaminobenzenesulfonyl chloride (17.3 g; 0.07403 mol) and NaHCO (15.6 g; 0.186 mol) dissolved in water
    (230 ml). The reaction mixture is stirred for 3 hours at the same temperature, the acetone is evaporated, and the product is distilled as in example 3. Yield 16.0 g (56.01%).
    Example9. Erythromycin dihydrochloride oxime A.
    Starting from 55.6 g (0.076 mol) of erythromycin A dissolved in methanol (280 ml), 15.7 g (0.226 mol) of hydroxylamine hydrochloride and 1.6 g (0.015 mol) of sodium carbonate (pH of the reaction mixture 5.5), in example 1, 30.0 g (48.3%) of erythromycin digidrochloride oxime A is obtained with the same physicochemical data as in example 1.
    I'll try it on. Erythromycin dihydrochloride oxime A.
    Starting from 44.4 g (0.06 mol) of erythromycin A, dissolved in 225 g of methanol, and 4.2 g (0.06 mol) of hydrochloride hydrochloride (pH of the reaction mixture, 6.3), example 1 gives 23 , 6 g (47.5%) of erythromycin dihydrochloride oxime A with the same physicochemical data as in example 1,
    Example 1 Erythromycin Dihydrochloride oxime A.
    Starting from 44.4 g (0.06 mol) of erythromycin A dissolved in methanol (225 ml) and 12.6 g (0.181 mol) of hydroxylaminohydrochloride (pH of the reaction mixture 5.0) was prepared by the method of example 1 22.5 g (45.2%) erythromycin dihydrochloride oxime A with the same physicochemical data as in example 1,
    Example 12 Erythromycin A Dihydrochloride A.
    Starting from 55.5 g (0.075 mol) of erythromycin A dissolved in methanol (280 ml), 12.6 g (0.181 mol) of hydroxylamine hydrochloride and 4.0 g (0.057 mol) of sodium carbonate (pH of the reaction mixture 6.5), in Example 1, 29.6 g (47.7) of erythromycin dihydrochloride oxime A are obtained with the same
    physico-chemical data as in example 1.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    The method of obtaining 7,16-diox-2-aza-IO-O-cladinosyl-12-0-desosaminyl-4,5-dihydroxy-6-ethyl-3,5,9,11,13, 15-hexamethylbenzyl 11,2 , 13hexadeca-1 (2) -en-8-one of formula
    CHj
    but
    N
    M1CH3) 2,
      S
    About SNS
     n
    HjCO SNS
    characterized in that
    to increase the yield of the target product and simplify the process, the erythromycin A oxime dihydrochloride obtained by oximating erythromycin A with a 1-5 molar excess of hydroxylamine hydrochloride in the presence of a 0-2 molar excess of sodium carbonate or barium in methanol at boiling point and pH of the reaction mixture 5.0-6.5, Beckmann rearrangement with a 2-4 molar excess of p-toluenesulfonyl chloride, p-irdbenzene-sulfonyl chloride or p-acetylaminobenzene sulfonyl chloride in the presence of a 2-8 molar excess of sodium bicarbonate
    or triethylamine at 0-5 C in a mixture of acetone and water.
    类似技术:
    公开号 | 公开日 | 专利标题
    EP0342990B1|1995-04-19|Process for preparing erythromycin A oxime or a salt therof
    RU2007398C1|1994-02-15|10-dihydro-10-desoxo-11-azaerythronolide a derivatives or pharmaceutically acceptable salts thereof and process for preparing same
    SU776557A3|1980-10-30|Method of preparing optically active anthracyclinones
    SE436874B|1985-01-28|N-SUBSTITUTED MORANOLINE DERIVATIVES
    DK146626B|1983-11-21|ANALOGY PROCEDURE FOR THE PREPARATION OF 4'-DEOXYDA UNOMYCINE
    SU1447288A3|1988-12-23|Method of producing 7,16-dioxy-2-aza-10-0-cladinoazyl-12-0-decozaminyl-4,5-dihydroxy-6-ethyl-3,5,9,11,13,15-hexamethylbicyclo[11,2,1] hexadeca-1|-ne-8-none
    DE2750812C2|1986-01-09|4-alkoxy-4-desmethoxydaunomycins and process for their preparation
    SU448639A3|1974-10-30|The method of obtaining amino-alcohol derivatives of o-trans-hydroxycinnamic acid
    SU648099A3|1979-02-15|Method of obtaining halogen derivatives of a-isolazalocide antibiotic
    SU650507A3|1979-02-28|Method of obtaining glycoside antibiotics or their hydrochlorides
    SU1055333A3|1983-11-15|Process for preparing leurozine-type alkaloids or their acid addition salts
    US4359416A|1982-11-16|Process for preparing L-carnosine
    SU1470179A3|1989-03-30|Method of producing tetramic acid
    SU986295A3|1982-12-30|Method of producing quinoline 6-oxoderivatives
    KR890001241B1|1989-04-28|Process for preparing 4-acetyl isoquinolinone
    SU552031A3|1977-03-25|Method for preparing benzimidazole derivatives
    RU2659783C1|2018-07-04|Process of preparation of 9-amino-2,3,5,6,7,8-hexahydro-1h-cyclopenta[b]quinoline chlorohydrate, hydrate
    SU436057A1|1974-07-15|METHOD OF OBTAINING ISOPROPYLIDENE DERIVATIVES OF PYRIDOXYN IN PT5FONM mmim
    SU1205770A3|1986-01-15|Method of producing 7-acetylspiro-| |=furann-2-| 1ъ-cyclopropan-3-on
    KR102283391B1|2021-07-30|New synthetic method of decursin derivatives
    SU753360A3|1980-07-30|Method of preparing 6,7-dimethoxy-4-amino-2/4-|-1-piperazinyl/-quinazoline
    SU1250170A3|1986-08-07|Method of producing pyrbuterol dichlorhydrate
    SU458130A3|1975-01-25|The method of obtaining nitrofurylpyriidine derivatives
    SU668596A3|1979-06-15|Method of producing oxime derivatives or salts thereof
    RU2021281C1|1994-10-15|Method of synthesis of oleandomycin oximes, and oleandomycin oximes
    同族专利:
    公开号 | 公开日
    PL143138B1|1988-01-30|
    HUT35692A|1985-07-29|
    JPS61148191A|1986-07-05|
    BA97167B1|1998-12-28|
    CA1231943A|1988-01-26|
    JPS6114155B2|1986-04-17|
    YU43658B|1989-10-31|
    SI8311553A8|1995-06-30|
    EP0137132A3|1986-04-02|
    EP0137132A2|1985-04-17|
    YU155383A|1985-10-31|
    HU194272B|1988-01-28|
    PL248784A1|1985-03-26|
    JPS6038393A|1985-02-27|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    RU2476438C2|2007-07-26|2013-02-27|Интервет Интернэшнл Б.В.|Solid forms of macrolides|YU43116B|1979-04-02|1989-04-30|Pliva Pharm & Chem Works|Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox|JPS6114155U|1984-07-02|1986-01-27|
    JPS6441442A|1987-08-04|1989-02-13|Takata Corp|Seat belt taking-up device|
    WO1994026758A1|1993-05-19|1994-11-24|Pfizer Inc.|Intermediate for azithromycin|
    US5441939A|1994-03-04|1995-08-15|Pfizer Inc.|3"-desmethoxy derivatives of erythromycin and azithromycin|
    HRP940251B1|1994-04-15|1998-12-31|Stjepan Mutak|Process for the preparation of azithromycin dihydrochloride|
    JP2001525332A|1997-12-01|2001-12-11|アボット・ラボラトリーズ|Chemical synthesis of 6-O-alkylerythromycin C|
    GB9824580D0|1998-11-10|1999-01-06|Biochemie Sa|Organic compounds|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    YU155383A|YU43658B|1983-07-18|1983-07-18|Process for preparing 7,16-dioxa-2-aza-10-0-cladinosyl-12,0-desosaminyl-4,5-dihydroxy-6-ethyl-3,5,9,11,13,15-hexamethyl-bicyclohexadeca-1-ene-8|
    [返回顶部]